Mark Buranosky, MD
Ophthalmology · Chicago, ILNPI 1558399949
Payments from drug & device makers
Across 182 payments — averaging $37.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- AbbVie$1K
- Novartis$719
- Alcon$646
- Harrow Eye, LLC$313
- Sun Pharmaceutical Industries Inc.$278
- plus $2K from 20 others
What the payments were for
- Consulting fees$1,06516%
- Travel & lodging$1,19618%
- Food & beverage$4,56067%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 15 | $1,618 |
| AbbVie(2 entities) | 19 | $1,148 |
| Novartis | 34 | $719 |
| Alcon | 21 | $646 |
| Harrow Eye, LLC | 13 | $313 |
| Sun Pharmaceutical Industries Inc. | 12 | $278 |
| Aerie Pharmaceuticals, Inc. | 8 | $253 |
| Oyster Point Pharma, Inc. | 10 | $230 |
| Bausch & Lomb Americas Inc. | 6 | $228 |
| Ocular Therapeutix, Inc. | 3 | $220 |
| Tarsus Pharmaceuticals, Inc. | 7 | $218 |
| Eyevance Pharmaceuticals LLC | 6 | $189 |
| Dompe US, Inc. | 3 | $171 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $158 |
| Glaukos Corporation | 3 | $98 |
| Sight Sciences, Inc. | 3 | $65 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $52 |
| Thea Pharma Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $36 |
| NEW World Medical,inc. | 3 | $25 |
| Akorn Operating Company LLC | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Carl Zeiss Meditec, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Johnson & Johnson Vision Care, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,332
- AmnioGraft$1,332
- AmnioGuard$1,332
- OZURDEX$865
- DEXTENZA$600
- Rocklatan$225
- Rhopressa$225
- Centurion$149
- MIEBO$125
- XIIDRA$125
- Oxervate$120
- Tecnis Symfony IOL$116
- Flarex$101
How this compares
$6,820 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 133 | $114,448 |
| LumiganBimatoprost | 143 | $60,413 |
| XiidraLifitegrast | 50 | $43,390 |
| RhopressaNetarsudil Mesylate | 57 | $21,415 |
| RocklatanNetarsudil Mesylat/Latanoprost | 44 | $21,274 |
| Cyclosporine | 44 | $18,651 |
| CombiganBrimonidine Tartrate/Timolol | 57 | $14,743 |
| VyzultaLatanoprostene Bunod | 31 | $11,913 |
| Alphagan PBrimonidine Tartrate | 17 | $7,350 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $7,008 |
| Prednisolone Acetate | 212 | $6,637 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $6,209 |
| Latanoprost | 468 | $5,883 |
| Travoprost | 39 | $4,869 |
| Brimonidine Tartrate | 89 | $2,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,148 | $196,955350 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $228 | $55,30381 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $253 | $42,689101 claims |
| AlconSimbrinza | $646 | $7,00826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Manjot GillChicago$1.4M
- Amani FawziChicago$864K
- Sarah SunshineChicago$664K
- Jennifer LimChicago$636K
- Dilraj GrewalChicago$543K
- Ahmad ArefChicago$355K
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Armin AfsharChicago$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.